Exagen Inc. last reported quarterly results on Aug 4, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): revenue of $19.9 million (+15.9% year over year) and diluted EPS of -$0.13. It usually reports 12–41 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 3, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Tuesday. Based on last year's release for the same quarter on Nov 4, 2025. The company has not filed these results with the SEC yet. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 12–41 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 4, 2026
35 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
20
+15.9%
|
-3
+28.0%
|
-0.13
+38.1%
|
|
May 11, 2026
41 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
17
+11.7%
|
-4
-5.7%
|
-0.17
+15.0%
|
|
Jan 12, 2026
12 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
17
+21.8%
|
-5
-24.2%
|
-0.20
+2.9%
|
|
Nov 4, 2025
35 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
17
+37.9%
|
-7
-41.0%
|
-0.31
-10.7%
|
|
Jul 29, 2025
29 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
17
+14.2%
|
-4
-49.7%
|
-0.21
-31.2%
|
|
May 5, 2025
35 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
15
+7.5%
|
-4
-11.7%
|
-0.20
-5.3%
|
|
Jan 13, 2025
13 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
14
-0.8%
|
-4
+32.5%
|
-0.20
+34.7%
|
|
Nov 12, 2024
43 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
13
-6.8%
|
-5
+7.1%
|
-0.28
+9.7%
|
Company profile
- Industry
- Services-Medical Laboratories (SIC 8071)
- Listed as
- XGN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Vista, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1274737
- Former names
- EXAGEN DIAGNOSTICS INC (until May 18, 2017)
Other Services-Medical Laboratories companies
- Natera, Inc. NTRA
- Labcorp Holdings Inc. LH
- Quest Diagnostics Inc DGX
- Guardant Health, Inc. GH
- Caris Life Sciences, Inc. CAI
- GRAIL, Inc. GRAL
- RadNet, Inc. RDNT
- BillionToOne, Inc. BLLN
Source: SEC EDGAR filings. This is company-reported data, not investment advice.